Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111602759 | 11160275 | 9 | F | 201505 | 20160915 | 20150603 | 20160919 | EXP | PHHY2015CA065555 | NOVARTIS | 73.03 | YR | F | Y | 0.00000 | 20160919 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111602759 | 11160275 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, QMO (ONCE A MONTH) | U | 21008 | 20 | MG | /month | ||||||
| 111602759 | 11160275 | 2 | SS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | 50 UG, BID (CONT. 2 WEEKS AFTER 1ST SAS LAR) | 0 | 50 | UG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111602759 | 11160275 | 1 | Gastrointestinal angiodysplasia |
| 111602759 | 11160275 | 2 | Gastrointestinal angiodysplasia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111602759 | 11160275 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111602759 | 11160275 | Asthenia | |
| 111602759 | 11160275 | Blood pressure diastolic decreased | |
| 111602759 | 11160275 | Blood pressure systolic increased | |
| 111602759 | 11160275 | Diabetes mellitus | |
| 111602759 | 11160275 | Dizziness | |
| 111602759 | 11160275 | Dysgraphia | |
| 111602759 | 11160275 | Dyspnoea | |
| 111602759 | 11160275 | Fall | |
| 111602759 | 11160275 | Fatigue | |
| 111602759 | 11160275 | Haemoglobin decreased | |
| 111602759 | 11160275 | Heart rate decreased | |
| 111602759 | 11160275 | Hypotension | |
| 111602759 | 11160275 | Nausea | |
| 111602759 | 11160275 | Pain | |
| 111602759 | 11160275 | Product use issue | |
| 111602759 | 11160275 | Pulmonary oedema | |
| 111602759 | 11160275 | Vertigo | |
| 111602759 | 11160275 | Visual impairment | |
| 111602759 | 11160275 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111602759 | 11160275 | 1 | 20150429 | 0 | ||
| 111602759 | 11160275 | 2 | 20150408 | 201505 | 0 |